Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Lymphoma 5Lymphoma, Large B-Cell, Diffuse 4Breast Neoplasms 4Sarcoma 3Ovarian Neoplasms 3Lymphoma, Mantle-Cell 3Lymphoma, Follicular 3Hodgkin Disease 3Triple Negative Breast Neoplasms 2Prostatic Neoplasms 2Multiple Myeloma 2Leukemia, Lymphocytic, Chronic, B-Cell 2Leukemia 2Burkitt Lymphoma 2Waldenstrom Macroglobulinemia 1Uterine Cervical Neoplasms 1Thyroid Carcinoma, Anaplastic 1Testicular Neoplasms 1Testicular Germ Cell Tumor 1Seminoma 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pain 1Osteosarcoma 1Neoplasm Metastasis 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, B-Cell, Marginal Zone 1

Interventions

Temozolomide 6Irinotecan 6Vincristine 3PM 01183 3Nivolumab 3X-Rays 2Cyclophosphamide 2temsirolimus 1talazoparib 1surufatinib 1silmitasertib 1seclidemstat 1rubitecan 1regorafenib 1pegylated granulocyte colony-stimulating factor 1pegfilgrastim 1liposomal doxorubicin 1irinotecan sucrosofate 1eribulin 1entrectinib 1efineptakin alfa 1dinutuximab 1copanlisib 1bempegaldesleukin 1anlotinib 1alovudine 1abemaciclib 1Zoledronic Acid 1Trabectedin 1Topotecan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Sarcoma, Ewing × pegfilgrastim × Clear all
NCT06709495 2026-02-19

Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas

Dana-Farber Cancer Institute

Phase 1/2 Recruiting
63 enrolled
Sarcoma

Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Desmoplastic Small Round Cell Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡